Xu Zhenyu 4

What Happened

• Zhenyu Xu, Chief Scientific Officer of SOPHiA GENETICS SA (SOPH), sold a total of 8,120 shares in mid-April 2026 for aggregate proceeds of approximately $38,374. The sales were executed on 2026-04-10 (3,706 shares at a weighted avg $4.68, ~$17,347) and 2026-04-13 (1,014 shares at $4.76, ~$4,830; and 3,400 shares at $4.76, ~$16,197). These were sales (not purchases) and represent routine dispositions rather than new acquisitions.

Key Details

• Transaction dates and reported amounts:
  • 2026-04-10: 3,706 shares sold, weighted avg price $4.68, proceeds ~$17,347.
  • 2026-04-13: 1,014 shares sold, weighted avg price $4.76, proceeds ~$4,830.
  • 2026-04-13: 3,400 shares sold, weighted avg price $4.76, proceeds ~$16,197.
• Total sold: 8,120 shares for ~ $38,374.
• Shares owned after transaction: Not specified in the information provided in your summary of the filing.
• Footnotes / notable items:
  • Sales were made pursuant to a pre-established Rule 10b5-1(c) trading plan and were to satisfy tax withholding obligations arising from restricted stock unit (RSU) vestings on April 2 and April 3, 2026.
  • Reported prices are weighted averages; the filings state sales were executed across price ranges of $4.61–$4.77 and $4.63–$4.88 for the transactions. The reporting person will provide per-price breakdowns upon written request (per the footnotes).
  • The Form 4 was filed on 2026-04-14; based on the transaction dates (April 10 and April 13) this filing appears timely under the two-business-day Form 4 rule.

Context

• These sales were tax-withholding dispositions tied to RSU vesting and executed under a pre-established 10b5-1 plan, which the filer states were non-discretionary. Such transactions are common for covering tax obligations and are generally viewed as routine rather than strong signals of insider sentiment.